NCT07656727: A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
- State
- Under way
- Phase
- Phase 2
- People
- 160 planned
- Started
- 11 Jun 2026
- Primary completion
- 30 Nov 2026
- Arms
- Arm A: BGE-102 Dose A, Arm B: BGE-102 Dose B, Arm C: BGE-102 Dose C
- Results
- None posted
- 11 Jun 2026: Trial started
- 18 Jun 2026: Trial registered